Exploratory analyses of predictors and correlates of response to omalizumab therapy in patients with multiple food allergies.

ABSTRACT:

Background

Stage 1 of the Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Children and Adults (OUtMATCH) study demonstrated that treatment with omalizumab for 16 to 20 weeks significantly increased the reaction threshold for peanut and other common food allergens in participants with multiple food allergies. However, the degree of this protection is variable across participants, and there are no known markers to predict or assess individual response to omalizumab.

Objective

Our aim was to evaluate clinical and laboratory-based variables as predictors or correlates of response to omalizumab treatment.

Methods

Cumulative tolerated dose (CTD) as a continuous variable and thresholds of 444 mg and 1044 mg of individual food proteins

SUBMITTER: Chinthrajah RS 

PROVIDER: S-EPMC12867313 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature